Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMD63 in Relapsed/Refractory Pediatric B-cell ALL
NCT07078929Phase 1Recruiting
- Sponsor
- Chulalongkorn University
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CMD63 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chulalongkorn University. Primary endpoint: Incidence and Severity of Adverse Events at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
CMD63
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07078929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07078929.